- A risk-benefit assessment of anti-obesity drugsJ Kolanowski
Endocrine Unit, Catholic University of Louvain, Brussels, Belgium
Drug Saf 20:119-31. 1999..Such a treatment is not available at present. Development of new agents and a more careful assessment of the safety of currently available drugs are needed...